Sophia Genetics-Dasa
Nov 2018 - May 2020
DASA, São Paulo, Brazil
SOPHiA for Radiomics is a groundbreaking application that analyzes medical images and combines them with biological and clinical data to predict tumor evolution. This powerful radiomic solution supports clinicians in choosing the right therapeutic strategy for a given patient. The aim of the pilot was to show that Radiomics for glioblastomas (GB) and Non-Small Cell Lung Cancer (NSCLC) , have the ability to enhance diagnosis, prognosis along with following the progression of the disease and assessing the therapeutic response. These applications have shown to be relevant for clinicians and radiologists at DASA.
Innovator
SOPHiA Genetics
Adopter
Dasa
Results
- A total of 149 patients’ data across GB and NSCLC patients were analyzed using SOPHiA Radiomics in this project.
- The project compared and cross validated performances of several machine learning algorithms developed in order to stratify glioblastomas as far as their molecular status is concerned and NSCLC as far as their histology is concerned.
- DASA also provided valuable feedback to the SOPHiA team, supporting the development of improved features and new developments such as:
- 50% efficiency gain to segment glioma patients (from 45’- 1 hour on V1 reduced to 30’ on average)
- Lung tumors segmentation improvements
- Multi-modal visualization and features extraction
- New radiomic features calculations
Lessons Learned
Through this project, SOPHiA GENETICS gathered on-field-feedback from the DASA team which was valuable in improving their platform and offering. To fully support the project, SOPHiA GENETICS made available a dedicated data scientist who supported the radiomic feature calculations. This has now been adopted as a standard proposed service to health institutions no matter their size or organizational structure, helping to efficiently manage the project in order to optimize clinicians’ time and allow them to access valuable patient data.
What partners say?
"SOPHiA Radiomics is a type of artificial intelligence that enables us to define tumor characteristics that could not see with the naked eye in a CT scan or MRI alone. This gives us much more valuable information about the tumor and how it will progress, and that informs our prognosis and the best treatment and survival for the patient."
"The TechEmerge project gave us the opportunity to introduce, install, and validate within DASA our SOPHiA Radiomics technology. Such innovative projects always require financing and strategic communications which were both enabled and catalyzed by the IFC thus helping us push these decisions forward."
Innovator in: TechEmerge Health Brazil
Share with others
